Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory

Analytical Biochemistry

Volumn 542, Issue , 2018, Pages 34-39

  Nikolaev, Sergey ^a   Lemmens, Laure ^a   Koessler, Thibaud ^a   Blouin, Jean Louis ^a   Nouspikel, Thierry ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cancer; Circulating tumor DNA; Diagnostic marker; Liquid biopsy; Preanalytical variables; Quality control

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG;

AMPLICON; ARTICLE; DNA DETERMINATION; HUMAN; LABORATORY; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; TEMPERATURE; TIME; BLOOD; GENETICS; NEOPLASM; VALIDATION STUDY;

CIRCULATING TUMOR DNA; HUMANS; LABORATORIES; NEOPLASMS; POLYMERASE CHAIN REACTION; QUALITY CONTROL;

EID: 85034831528     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2017.11.004     Document Type: Article

References (10)

1. Crowley, E., Di Nicolantonio, F., Loupakis, F., Bardelli, A., Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10 (2013), 472–484, 10.1038/nrclinonc.2013.110.
2. Lebofsky, R., Decraene, C., Bernard, V., et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol. Oncol. 9 (2015), 783–790, 10.1016/j.molonc.2014.12.003.
3. De Mattos-Arruda, L., Weigelt, B., Cortes, J., et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 25 (2014), 1729–1735, 10.1093/annonc/mdu239.
4. Diehl, F., Schmidt, K., Choti, M.A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S.A., Kinzler, K.W., Vogelstein, B., Diaz, L.A. Jr., Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14 (2008), 985–990, 10.1038/nm.1789.
5. Reinert, T., Schøler, L.V., Thomsen, R., et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65 (2016), 625–634, 10.1136/gutjnl-2014-308859.
6. Bettegowda, C., Sausen, M., Leary, R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med., 6, 2014 Feb 19, 224, 10.1126/scitranslmed.3007094 ra24.
7. Rothé, F., Laes, J.F., Lambrechts, D., Smeets, D., et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann. Oncol. 25 (2014), 1959–1965, 10.1093/annonc/mdu288.
8. Devonshire, A.S., Whale, A.S., Gutteridge, A., Jones, G., Cowen, S., Foy, C.A., Huggett, J.F., Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal. Bioanal. Chem. 406 (2014), 6499–6512, 10.1007/s00216-014-7835-3.
9. Heitzer, E., Ulz, P., Geigl, J.B., Circulating tumor DNA as a liquid biopsy for cancer. Clin. Chem. 61 (2015), 112–123, 10.1373/clinchem.2014.222679.
10. Norton, S.E., Lechner, J.M., Williams, T., Fernando, M.R., A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin. Biochem. 46 (2013), 1561–1565, 10.1016/j.clinbiochem.2013.06.002.